149 compounds. Every one graded.

Full-length adrenal hormone with broad receptor activity

ACTH 1-39 is the full-length, biologically active form of adrenocorticotropic hormone, a 39-amino acid peptide naturally secreted by the anterior pituitary gland. It primarily stimulates the adrenal cortex to produce cortisol, aldosterone, and adrenal androgens. Beyond adrenal signaling, ACTH 1-39 exerts direct effects on the brain, immune system, and peripheral tissues via melanocortin receptors.

Once-weekly amylin analogue for weight loss

Cagrilintide is a long-acting acylated amylin analogue developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It mimics the pancreatic hormone amylin to reduce appetite, slow gastric emptying, and promote satiety. In clinical trials, it has been studied both as a monotherapy and in combination with semaglutide (as CagriSema), demonstrating meaningful and sustained body weight reduction.

Dual amylin-GLP-1 therapy for superior weight loss

Cagrisema is a fixed-ratio combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), each at 2.5 mg per dose. This dual-hormone therapy is designed to provide additive and potentially synergistic effects on appetite suppression, glycemic control, and body weight reduction beyond what either agent achieves alone. It is currently under clinical investigation by Novo Nordisk for the treatment of obesity and type 2 diabetes.

Preserve natural testosterone via HPG axis activation

Gonadorelin Acetate is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH), produced and secreted by the hypothalamus. It stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby supporting endogenous testosterone and estrogen production. It is used clinically to assess pituitary function, treat hypogonadism, support fertility, and is increasingly used alongside anabolic protocols to preserve testicular function.

The LH Mimic for Hormonal Restoration

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced by the placenta during pregnancy, structurally similar to luteinizing hormone (LH). In clinical and research settings, it is used to stimulate testosterone production in men, support fertility, and maintain testicular function during or after anabolic steroid use. It acts directly on the gonads to mimic LH signaling, making it a cornerstone of hormonal restoration protocols.

Dual GLP-1/glucagon agonist for metabolic health

Mazdutide is a dual GLP-1/glucagon receptor co-agonist peptide developed by Innovent Biologics, originally derived from oxyntomodulin. It simultaneously activates both GLP-1 and glucagon receptors to produce robust reductions in body weight, blood glucose, and hepatic fat. Clinical trials in China have demonstrated significant efficacy for obesity and type 2 diabetes management.

Clinical-grade melanocyte activator for photoprotection

Melanotan I (afamelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that potently stimulates melanogenesis, increasing skin pigmentation without requiring UV exposure. It was developed primarily to protect individuals with photosensitive conditions such as erythropoietic protoporphyria (EPP) from painful phototoxic reactions. Beyond tanning, it has demonstrated anti-inflammatory, photoprotective, and potentially immunomodulatory effects in clinical and preclinical studies.

GnRH analogue for hormonal axis modulation

Triptorelin Acetate is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) used clinically to treat hormone-sensitive conditions such as prostate cancer, endometriosis, and central precocious puberty. Upon initial administration it causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), followed by sustained suppression of gonadal steroid production through pituitary receptor desensitization. In research and off-label contexts, single low-dose administration has been explored as a means to transiently restore hypothalamic-pituitary-gonadal (HPG) axis function in individuals with post-anabolic-steroid-induced hypogonadism.

AMPK activator mimicking endurance exercise effects

AICAR (Acadesine) is a nucleoside analog and potent AMPK activator that mimics the cellular energy-depletion state, triggering a cascade of metabolic adaptations including enhanced fatty acid oxidation and mitochondrial biogenesis. It has been extensively studied for its ability to improve endurance performance, insulin sensitivity, and metabolic flexibility without physical exercise. Originally developed as a cardioprotective agent, it has attracted significant interest in the performance and longevity research communities.

Fat-targeting hGH fragment for metabolic support

AOD9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (amino acids 176–191), developed originally by Monash University as an anti-obesity drug. It mimics the lipolytic (fat-burning) effects of growth hormone without stimulating IGF-1 production or promoting cell proliferation. Research suggests it stimulates fat breakdown and inhibits fat formation, with a favorable safety profile compared to full-length hGH.

Targeted fat-loss fragment of growth hormone

HGH Fragment 176-191 is a synthetic peptide derived from amino acids 176–191 of the C-terminus of human growth hormone (hGH). It was specifically engineered to retain the lipolytic (fat-burning) properties of hGH while eliminating its growth-promoting and insulin-desensitizing effects. Research, primarily in animal models, suggests it stimulates fat breakdown and inhibits the formation of new fat cells.

Endogenous HPG axis activator for sexual health

Kisspeptin-10 is the biologically active C-terminal decapeptide fragment of the larger kisspeptin precursor protein, encoded by the KISS1 gene. It acts as a potent endogenous activator of the hypothalamic-pituitary-gonadal (HPG) axis, stimulating the release of gonadotropin-releasing hormone (GnRH) and downstream luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is investigated for applications in reproductive endocrinology, sexual function, and mood regulation.

Lipotropic blend for fat loss and liver health

Lipo-C is a lipotropic injection blend combining several compounds—typically methionine, inositol, choline, carnitine, and B vitamins—designed to support fat metabolism and liver function. It promotes the mobilization and breakdown of fat deposits, particularly in the liver. The formulation is commonly used in weight loss programs to enhance lipolysis and improve metabolic efficiency.

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

Targeted fat-depot elimination via vascular apoptosis

Adipotide is a pro-apoptotic peptidomimetic designed to selectively destroy the blood supply feeding white adipose tissue (WAT), causing fat cell death through targeted vascular disruption. It was developed at MD Anderson Cancer Center primarily as an anti-obesity compound and has shown dramatic fat loss in non-human primate studies. Human clinical data remains extremely limited, and it is considered a research compound only.

The Master Brake on Muscle Growth

GDF-8, also known as myostatin, is a TGF-β superfamily member that acts as a potent negative regulator of skeletal muscle mass. It limits muscle fiber size and number by inhibiting myoblast proliferation and differentiation. Research into myostatin inhibition has generated significant interest for applications in muscle wasting diseases, metabolic disorders, and athletic performance.

Selective cancer cell membrane-targeting peptide

PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, designed to selectively induce apoptosis in cancer cells while leaving normal cells unharmed. It contains an MDM-2-binding domain of p53 fused to a transmembrane-penetrating sequence, enabling it to insert into the membranes of cancer cells that aberrantly express HDM-2 on their surface. Research has been conducted primarily in vitro and in animal models, with very limited human data available.

Exercise mimetic targeting mitochondrial energy pathways

SLU-PP-322 is a synthetic small-molecule agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ) developed at Saint Louis University. It mimics the metabolic effects of sustained aerobic exercise at the cellular level, promoting mitochondrial biogenesis, fatty acid oxidation, and endurance capacity without physical activity. In preclinical animal studies, it has demonstrated significant improvements in exercise performance, fat metabolism, and cardiac function.

Mitochondrial peptide for metabolic and renal health

Mitochondrial-targeted peptide for metabolic & kidney protection.

Experimental GH fragment targeting fat metabolism

Frag 17-23 is a short synthetic peptide fragment derived from amino acids 17 through 23 of the human growth hormone (hGH) sequence. It is hypothesized to retain lipolytic properties similar to larger hGH fragments while being structurally distinct from the more widely studied Frag 176-191. Evidence for its efficacy in humans remains largely anecdotal, with minimal published research specific to this fragment.

Electrolyte balance and cardiovascular metabolic support

KLOW is a research compound or proprietary peptide blend purported to support electrolyte balance, cardiovascular function, and cellular metabolic homeostasis. It is marketed within the peptide research space, though its precise composition and mechanism are not well-established in peer-reviewed literature. Evidence for its specific effects remains largely anecdotal and preclinical.

Mitochondrial-encoded peptide for glucose control

Mitochondrial-derived peptide for metabolic regulation & insulin sensitivity.